> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-21/
- Published: 2020-05-25T12:00:00.000Z
- Updated: 2026-09-14T16:15:50.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141068

**Boston Scientific** has agreed to acquire **NxThera**, a privately-held company based in Maple Grove, MN for $306 million upfront and an additional $100 million in potential commercial milestone payments over the next four years. The transaction gives Boston Scientific the Rez?m, a treatment system for men with symptoms arising from benign prostatic hyperplasia.

**Cipher Pharmaceuticals** has agreed to acquire **Cardiome Pharma**’s Canadian business portfolio of Cardiome. The transaction will give Cipher access to commercial and pipeline hospital products administered in the acute care setting, including Brinavess (vernakalant IV), Aggrastat (tirofiban hydrochloride), Xydalba (dalbavancin hydrochloride), and Trevyent (treprostinil).

**GlaxoSmithKline** is backing away from any bid to acquire **Pfizer**’s consumer health business, which is valued between $15 and $20 billion. The British pharma giant’s announcement followed a similar announcement from potential suitor **Reckitt Benckiser Group**.